Powered by OpenAIRE graph
Found an issue? Give us feedback

University of Birmingham

University of Birmingham

Funder
Top 100 values are shown in the filters
Results number
arrow_drop_down
3,927 Projects, page 1 of 786
  • Funder: European Commission Project Code: 328959
    more_vert
  • Funder: UK Research and Innovation Project Code: 2286807

    Not disclosed

    more_vert
  • Funder: UK Research and Innovation Project Code: G0701275
    Funder Contribution: 347,312 GBP

    We are trying to understand how proteins called antibodies and the cells that make them work to protect against Salmonella infections. This should help improve vaccines against Salmonella and other bacteria since nearly all vaccines work via antibody. Salmonella infections can have deadly consequences killing hundreds of thousands around the world yearly. In some cases if Salmonella is found in an infant’s blood then that child has a near 25% chance of dying. Salmonella travels through the blood to infect and grow in many sites such as the liver or spleen. Yet the body is not defenceless against this spread because antibodies can bind Salmonella and lead to its killing. But to be effective the antibody needs to be present before the infection and this can be achieved by vaccination. Using a mouse model, since these complex events cannot be effectively mimicked in other systems, we have found that antibodies to some Salmonella proteins can prevent infection and may help us design an effective, safe vaccine. Since these Salmonella proteins and the cells that make the antibody have some unusual properties we hope that these studies may help us better understand how we fight bacteria and then use this information to design vaccines to other bacterial diseases.

    more_vert
  • Funder: UK Research and Innovation Project Code: G1100247
    Funder Contribution: 1,248,520 GBP

    Hepatitis C virus (HCV) is a globally important virus that infects 170 million individuals world wide, resulting in progressive chronic liver disease. At present, there are limited therapies available for treating hepatitis C and there is an urgent need for the development of new agents that will cure infection. Viruses initiate infection by attaching to molecules or receptors on the cell surface, providing a target for therapeutic intervention. Recent advances have identified the cellular molecules defining HCV entry into liver cells. Studies from our laboratory have shown that HCV strains differ in their interaction with host cell receptors and this will have significant consequences for virus infectivity and spread in the liver. We hypothesise that such differences in HCV-receptor interactions will influence the ?relative fitness? of a virus to transmit and infect new individuals. We will use molecular and biological methods to study transmitting HCV strains to increase our understanding of the molecular events that define and limit virus transmission.

    more_vert
  • Funder: European Commission Project Code: 326847
    more_vert
  • chevron_left
  • 1
  • 2
  • 3
  • 4
  • 5
  • chevron_right

Do the share buttons not appear? Please make sure, any blocking addon is disabled, and then reload the page.

Content report
No reports available
Funder report
No option selected
arrow_drop_down

Do you wish to download a CSV file? Note that this process may take a while.

There was an error in csv downloading. Please try again later.